Fortress Biotech, Inc. (FBIOP) Stock Price & Analysis
Fortress Biotech, Inc. (FBIOP) — MoonshotScore 35/100 (Weak band), calculated Oct 5, 2026. Price $16.86 (+4.98%), as of the Oct 2, 2026 trading session; market cap $133M.
Educational signal · not a buy or sell recommendation · How to read this
Fortress Biotech, Inc. · FBIOP
Fortress Biotech, Inc. is a biopharmaceutical company focused on developing and commercializing pharmaceutical and biotechnology products, including dermatology treatments and oncology therapies. The company operates through a network of subsidiary companies and collaboration arrangements to advance its pipeline.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Fortress Biotech (FBIOP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, but a strained balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $19M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 6 of 8
- Altman Z -1.15 · Piotroski F 5
Helping: business quality, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 35 | Weak | |
| 35 | Weak |
The score was 35 in the stored Oct 4, 2026 snapshot and remains 35 in the current publication computed Oct 5, 2026 (0). This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $16.86 | |
| Change on the day | +4.98% | |
| 52-week range | $6.27 – $21.43 | |
| Market capitalisation | $133M | |
| Price / earnings (trailing) | 0.62 | |
| Shares traded on the day | 25.0K |
Price & events
Council Score · weighted blend of 2 available disciplines
Council score for Fortress Biotech (FBIOP): Split View
41/100 · CSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Simons-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the FBIOP film — every key number, told as a short cinematic story
~2 min · open the film
What is Fortress Biotech (FBIOP), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Fortress Biotech, Inc. (FBIOP) is the company analyzed here. It employs 78 people and is led by Lindsay A. Rosenwald. In Q2 FY2026 it reported revenue of $19M and net income of -$468,000. The market values it at $133M.
What do the latest results show for Fortress Biotech (FBIOP)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $19M. Against analyst estimates the company has EPS beat 6 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $19M | -$468,000 | -$0.01 (diluted) |
| Q1 FY2026 | $16M | $110M | $2.87 (diluted) |
| Q4 FY2025 | $16M | -$4M | -$0.11 (diluted) |
| Q3 FY2025 | $18M | $6M | $0.18 (diluted) |
What are the financial strengths and risks for Fortress Biotech (FBIOP)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, positive momentum as strengths. The distress and quality screens read Altman Z -1.15 · Piotroski F 5. Trailing ratios: ROE 163.9% · ROA 35.8% · current ratio 2.86 · earnings yield 132.4%.
How does Fortress Biotech compare with its peers?
Short answer
Fortress Biotech's score ranks 2nd of 5 in the bounded comparison shown, against 4 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1.41 Oct 2, 2026 | $89.2M | 46 5-pillar Oct 5, 2026 | |
| Fortress Biotech (FBIOP) — this page | $16.86 | $133M | 35 |
| $1.53 Oct 2, 2026 | $277M | 30 5-pillar Oct 5, 2026 | |
| $0.74 Oct 2, 2026 | $14.3M | 27 5-pillar Oct 5, 2026 | |
| $25.57 Oct 2, 2026 | $186M | 16 5-pillar Oct 5, 2026 | |
| $10.99 Sep 9, 2026 | $38.6M | — Model unavailable | |
| $9.96 Date unavailable | $119M | — Model unavailable | |
| $4.49 Date unavailable | $184M | — Model unavailable | |
| $17.08 Date unavailable | $90.6M | — Model unavailable | |
| $9.75 Date unavailable | $88.2M | — Model unavailable | |
| $5.71 Date unavailable | $206M | — Model unavailable | |
| $2.71 Date unavailable | $218M | — Model unavailable | |
| $2.79 Date unavailable | $222M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Fortress Biotech (FBIOP)?
Common Questions About FBIOP
These answers are editorial: 1 of these 9 answers is drawn from the FBIOP research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for FBIOP?
FBIOP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is FBIOP a good stock to buy?
Stock Expert AI does not rate FBIOP buy, sell or hold. Fortress Biotech, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the FBIOP stock price today?
The last price recorded on this page for Fortress Biotech, Inc. (FBIOP) is $16.86, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for FBIOP?
The main risks for Fortress Biotech, Inc. include clinical trial failures, regulatory setbacks, and market competition. The company's success depends on the successful development and commercialization of its product candidates, which are subject to regulatory approval. Investors should carefully consider these risks before investing in FBIOP.
What are the key factors to evaluate for FBIOP?
Fortress Biotech, Inc. (FBIOP) holds a MoonshotScore in the low range. P/E: 0.62x. Not financial advice.
How frequently does FBIOP data refresh on this page?
FBIOP's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven FBIOP's recent stock price performance?
Fortress Biotech, Inc. (FBIOP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline of product candidates. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FBIOP overvalued or undervalued right now?
Fortress Biotech, Inc. (FBIOP) trades at 0.62x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research FBIOP before investing?
Before investing in Fortress Biotech, Inc. (FBIOP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (18 figures)
The 18 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 10 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $16.86 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T17:14:29.134Z. | |
px.change | Change on the day | +4.98% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $133M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T17:14:28.017Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.80 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $19M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 0.62 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 25.0K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$468,000 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 12 transactions · 0 purchases, 0 sales, 12 other transactions · 8 identified insiders · most recent available transactions | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-08 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -1.15 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-08-14 · Expired observation | |
px.range52 | 52-week range | $6.27 – $21.43 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.employees | Employees | 78 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.ceo | Chief executive | Lindsay A. Rosenwald | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 163.9% · ROA 35.8% · current ratio 2.86 · earnings yield 132.4% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 35 of 100 · Weak · pillars 90 / 38 / 74 / 55 / 84 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 35 (stored snapshot Oct 4, 2026) → 35 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.